While the FTC would no doubt disallow TEVA from "cornering the market" on generic versions of enox (and Copaxone?),
I'm not sure on what basis the FTC would object. As of today, because Sandoz has all the licenses for the technology for Enox and I'd assume copax if Momenta has any roll in either drug from a production point of view.
I really don't have a clue what the current roll that Momenta plays in Copax. It probably has little roll in Enox.